1. Рафальский В.В., Страчунский Л.С., Бабкин П.А. и др. Резистентность возбудителей неосложненных инфекций мочевых путей в России. Урология. 2006; 34–7.
2. Рафальский В.В., Белокрысенко С.С., Малев И.В. и др. Чувствительность возбудителей инфекций мочевыводящих путей, выделенных в Российской Федерации, к пероральному цефалоспорину III поколения цефиксиму. Леч. врач. 2008; 27–9.
3. Justice SS, Hunstad DA, Seed PC, Hultgren SJ. Filamentation by Escherichia coli subverts innate defenses during urinary tract infection. Proc Nation Acad Sci 2006; 103: 19884–9.
4. Piatti G, Mannini A, Balistreri M, Schito AM. Virulence Factors in Urinary Escherichia coli Strains: Phylogenetic Background and Quinolone and Fluoroquinolone Resistance. J Clin Microbiol 2008; 46: 480–7.
5. Garofalo CK, Hooton TM, Martin SM et al. Escherichia coli from Urine of Female Patients with Urinary Tract Infections Is Competent for Intracellular Bacterial Community Formation. Infect Immun 2007; 75: 52–60.
6. Blango MG, Mulvey MA. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 54: 1855–63.
7. Moreau JL, Royer-Morrot MJ, Lozniewski A et al. Penetration of pefloxacin and its desmethyl metabolite into the uroepithelium after a 800 mg single oral dose in human patients. Eur J Clin Pharmacol 1996; 49: 401–5.
8. Hattori T, Kimura G, Kondo Y et al. Urothelial mucosal concentration of levofloxacin administered before transurethral resection: Is the mucosal concentration predictable? Int J Urol 2001; 8: 171–6.
9. Рафальский В.В., Ходневич Л.В. Влияние резистентности возбудителей инфекций мочевыводящих путей на исходы антибактериальной терапии. Урология. 2008; 3–9.
10. Yamamoto S, Akiyama K, Yoshimoto T et al. Clinical efficacy of oral administration of 200 mg gatifloxacin once daily for 3 days for the treatment of patients with uncomplicated cystitis. J Infect Chemother 2009; 15: 104–7.
11. Рафальский В.В., Малев И.В., Деревицкий А.В. и др. Эффективность норфлоксацина при остром цистите в регионе с 10% уровнем резистентности E. coli к фторхинолонам: сравнительное рандомизированное исследование. Урология. 2009; 18–21.
12. Raz R, Rottensterich E, Boger S, Potasman I. Comparison of single-dose administration and three-day course of amoxicillin with those of clavulanic acid for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 1991; 35: 1688–90.
13. Casas Rodriguez J, Pallares Robles J, Guarga Rojas A et al. Amoxicillin/clavulanic acid and trimethoprim in the treatment of urinary infection in primary care. Aten Primaria 1990; 7: 127–30.
14. Warren JW, Abrutyn E, Hebel JR et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29: 745–58.
15. Frimodt-Moller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 2002; 19: 546–53.
16. Iravani A, Klimberg I, Briefer C et al. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother 1999; 43: 67–75.
17. Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007; 167: 2207–12.
18. Masterton RG, Bochsler JA. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother 1995; 35: 129–37.
19. Hooton TM, Scholes D, Gupta K et al. Amoxicillin-Clavulanate vs Ciprofloxacin for the Treatment of Uncomplicated Cystitis in Women: A Randomized Trial. Jama 2005; 293: 949–55.
20. Williams KJ, Hebblethwaite EM, Brown GW et al. Cefuroxime axetil in the treatment of uncomplicated UTI: a comparison with cefaclor and augmentin. Drugs Exp Clin Res 1987; 13: 95–9.
21. Rafalsky V, Andreeva I, Rjabkova E. Quinolones for uncomplicated acute cystitis in women. Cochrane Database Syst Rev 2006; 3: CD003597.
22. Karlowsky JA, Kelly LJ, Thornsberry C et al. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46: 2540–5.
23. Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int J Antimicrob Agents 2003; 22 (Suppl. 2): 49–52.
24. Farrell DJ, Morrissey I, De Rubeis D et al. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect 2003; 46: 94–100.
25. Zhanel GG, Hisanaga TL, Laing NM et al. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2005; 26: 380–8.
26. Bottiger LE, Westerholm B. Adverse drug reactions during treatment of urinary tract infections. Eur J Clin Pharmacol 1977; 11: 439–42.
27. Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002; 65: 455–64.
28. Fluoroquinolones. In: Drug facts and compariton, 2007 Edition. St. Louis Missouri, USA, Wolter Kluwer Health, 2007.
29. Vanessa A, Caroline P. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 2008; 68: 535–65.
30. Montay G, Goueffon Y, Roquet F. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother 1984; 25: 463–72.
31. Hofbauer H, Naber KG, Kinzig-Schippers M et al. Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800 mg oral dose. Infection 1997; 25: 121–6.
32. EMEA. PRESS RELEASE: EMEA recommends restricted use of oral norfloxacin-containing medicines in urinary infections 2008.